Targeted Multiplexed Selected Reaction Monitoring Analysis Evaluates Protein Expression Changes of Molecular Risk Factors for Major Psychiatric Disorders
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Extensive research efforts have generated genomic, transcriptomic, proteomic, and functional data hoping to elucidate psychiatric pathophysiology. Selected reaction monitoring, a recently developed targeted proteomic mass spectrometric approach, has made it possible to evaluate previous findings and hypotheses with high sensitivity, reproducibility, and quantitative accuracy. METHODS: Here, we have developed a labelled multiplexed selected reaction monitoring assay, comprising 56 proteins previously implicated in the aetiology of major psychiatric disorders, including cell type markers or targets and effectors of known psychopharmacological interventions. We analyzed postmortem anterior prefrontal cortex (Brodmann area 10) tissue of patients diagnosed with schizophrenia (n=22), bipolar disorder (n=23), and major depressive disorder with (n=11) and without (n=11) psychotic features compared with healthy controls (n=22). RESULTS: Results agreed with several previous studies, with the finding of alterations of Wnt-signalling and glutamate receptor abundance predominately in bipolar disorder and abnormalities in energy metabolism across the neuropsychiatric disease spectrum. Calcium signalling was predominantly affected in schizophrenia and affective psychosis. Interestingly, we were able to show a decrease of all 4 tested oligodendrocyte specific proteins (MOG, MBP, MYPR, CNPase) in bipolar disorder and to a lesser extent in schizophrenia and affective psychosis. Finally, we provide new evidence linking ankyrin 3 specifically to affective psychosis and the 22q11.2 deletion syndrome-associated protein septin 5 to schizophrenia. CONCLUSIONS: Our study highlights the potential of selected reaction monitoring to evaluate the protein abundance levels of candidate markers of neuropsychiatric spectrum disorders, providing a high throughput multiplex platform for validation of putative disease markers and drug targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Skyline: an open source document editor for creating and analyzing targeted proteomics experiments
MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M., Finney, G. L., Frewen, B., Kern, R., Tabb, D. L., Liebler, D. C., & MacCoss, M. J. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq054 · Cited by 4,697
(2013) · The Lancet · doi:10.1016/s0140-6736(12)62129-1 · Cited by 3,010 · cited 2×
“Symptom profiles greatly overlap with regards to clinical psychopathology as well as putative pathophysiology (Smoller et al., 2013).”
Backgroundvan Os, J., & Kapur, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60995-8 · Cited by 1,971
Decreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636
Selected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions
Picotti, P., & Aebersold, R. (2012) · Nature Methods · doi:10.1038/nmeth.2015 · Cited by 1,302 · cited 2×
“In contrast to shot-gun proteomics strategies, in which the goal is to simultaneously investigate abundance changes of hundreds to thousands of proteins at the expense of sensitivity, SRM mass spectrometry platforms allow monitoring of a predetermined selection of proteins/peptides with high sensitivity, reproducibili…”
BackgroundThe genetics of depression: A review
Levinson, D. F. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.024 · Cited by 855 · cited 2×
“These disorders are heterogeneous in nature, with genetic and environmental factors contributing to pathogenesis and aetiology (Levinson, 2006; van Os and Kapur, 2009; Kim et al., 2011; Craddock and Sklar, 2013; Klengel and Binder, 2013).”
BackgroundWhite Matter Changes in Schizophrenia: Evidence for Myelin-Related Dysfunction
Davis, K. L., Stewart, D. G., Friedman, J. I., Buchsbaum, M., Harvey, P. D., Hof, P. R., Buxbaum, J., & Haroutunian, V. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.5.443 · Cited by 793
Kreisel, T., Frank, M. G., Licht, T., Reshef, R., Ben-Menachem-Zidon, O., Baratta, M. V., Maier, S. F., & Yirmiya, R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.155 · Cited by 663 · cited 2×
“After dissolving the precipitate in 50 mM ammonium bicarbonate, protein concentrations were determined in quadruplets.”
BackgroundMethodSchizophrenia susceptibility associated with interstitial deletions of chromosome 22q11.
Karayiorgou, M., Morris, M. A., Morrow, B., Shprintzen, R. J., Goldberg, R., Borrow, J., Gos, A., Nestadt, G., Wolyniec, P. S., & Lasseter, V. K. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7612 · Cited by 628 · cited 1×
“2 Deletion Syndrome develop SZ-like symptoms (Karayiorgou et al., 1995; Ivanov et al., 2003; Horowitz et al., 2005).”
Myelination of Cortical-hippocampal Relays During Late Adolescence
Benes, F. M. (1989) · Schizophrenia Bulletin · doi:10.1093/schbul/15.4.585 · Cited by 448
Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination
Fancy, S. P. J., Harrington, E. P., Yuen, T. J., Silbereis, J. C., Zhao, C., Baranzini, S. E., Bruce, C. C., Otero, J. J., Huang, E. J., Nusse, R., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2855 · Cited by 349 · cited 2×
“The compound XAV939 has been shown to enhance oligodendrocyte differentiation and remyelination by stabilizing Axin2, an intracellular target of Wnt transcriptional activation (Fancy et al., 2011).”
BackgroundMethodMicroglial Dysregulation in Psychiatric Disease
Frick, L. R., Williams, K., & Pittenger, C. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/608654 · Cited by 299 · cited 1×
“We provide evidence for microglial dysfunction in MDD (Frick et al., 2013; Kreisel et al., 2013) compared with controls as shown by a decrease in coronin 1A levels.”
BackgroundMecha, M., Torrao, A. S., Mestre, L., Carrillo-Salinas, F. J., Mechoulam, R., & Guaza, C. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.71 · Cited by 140
Bennett, V., & Lambert, S. (1999) · Journal of Neurocytology · doi:10.1023/a:1007005528505 · Cited by 109 · cited 2×
“The ANK3 protein is involved in neuronal scaffolding and the formation and maintenance of the axon initial segment of neurons and nodes of Ranvier (Bennett and Lambert, 1999).”
BackgroundSchizophrenia Genetics: Where Next?
Kim, Y., Zerwas, S., Trace, S. E., & Sullivan, P. F. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr031 · Cited by 101
Molecular and genetic evidence for abnormalities in the nodes of Ranvier in schizophrenia
Roussos, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.110 · Cited by 93 · cited 1×
“Heavy labelled forms of the selected peptides (spiketides L) were chemically synthesized via SPOT synthesis (JPT Peptide Technologies GmBH, Berlin, Germany).”
Method
Cited by
Enache, D., Pariante, C. M., & Mondelli, V. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.06.015 · Cited by 615
“We included 8 studies which investigated microglial markers in post-mortem brains of patients with MDD (Brisch et al., 2017; Busse et al., 2015; Clark et al., 2016; Foster et al., 2006; Steiner et al., 2011, 2008; Torres-Platas et al., 2014; Wesseling et al., 2014)(Table 4).”
BackgroundResultInfluentialZuccoli, G. S., Saia-Cereda, V. M., Nascimento, J. M., & Martins-de-Souza, D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00493 · Cited by 157
“…al., 2015), 10 on BPD (Johnston-Wilson et al., 2000; Beasley et al., 2006; Pennington et al., 2008a; Behan et al., 2009; Föcking et al., 2011, 2016; Wesseling et al., 2014; Gottschalk et al., 2015; Schubert et al., 2015; Stelzhammer et al., 2015), and seven on MDD (Johnston-Wilson et al., 2000;…”
BackgroundAl Shweiki, M. R., Steinacker, P., Oeckl, P., Hengerer, B., Danek, A., Fassbender, K., Diehl-Schmid, J., Jahn, H., Anderl-Straub, S., Ludolph, A. C., et al. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.03.019 · Cited by 131
Kahl, K. G., Stapel, B., & Frieling, H. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.09.004 · Cited by 47
Sustained Molecular Pathology Across Episodes and Remission in Major Depressive Disorder
Scifo, E., Pabba, M., Kapadia, F., Ma, T., Lewis, D. A., Tseng, G. C., & Sibille, E. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.008 · Cited by 41
Metadata
- Authors
- Wesseling, H., Gottschalk, M. G., & Bahn, S.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-12-19
- Volume
- 18
- Issue
- 1
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2290314528
- Cited by
- 53
- References
- 16
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.